IRIS
CIVES, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.814
AS - Asia 1.669
EU - Europa 1.045
SA - Sud America 514
AF - Africa 65
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.114
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.758
SG - Singapore 685
BR - Brasile 431
CN - Cina 399
HK - Hong Kong 246
SE - Svezia 220
RU - Federazione Russa 190
IT - Italia 189
VN - Vietnam 146
GB - Regno Unito 94
DE - Germania 90
FI - Finlandia 57
FR - Francia 44
ID - Indonesia 44
AR - Argentina 35
IN - India 32
CA - Canada 30
BD - Bangladesh 25
CI - Costa d'Avorio 25
AT - Austria 22
BE - Belgio 21
JP - Giappone 21
NL - Olanda 20
PL - Polonia 20
UA - Ucraina 19
ZA - Sudafrica 19
IQ - Iraq 18
MX - Messico 18
TR - Turchia 14
IE - Irlanda 13
LT - Lituania 12
CO - Colombia 10
ES - Italia 9
PY - Paraguay 9
EC - Ecuador 8
MA - Marocco 8
CL - Cile 6
PK - Pakistan 6
VE - Venezuela 6
MK - Macedonia 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
OM - Oman 4
RS - Serbia 4
UY - Uruguay 4
HU - Ungheria 3
KE - Kenya 3
PE - Perù 3
SA - Arabia Saudita 3
TH - Thailandia 3
TN - Tunisia 3
AU - Australia 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
ET - Etiopia 2
GR - Grecia 2
IL - Israele 2
KZ - Kazakistan 2
LB - Libano 2
NZ - Nuova Zelanda 2
RO - Romania 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JO - Giordania 1
MT - Malta 1
NP - Nepal 1
PS - Palestinian Territory 1
QA - Qatar 1
SN - Senegal 1
SO - Somalia 1
TV - Tuvalu 1
TW - Taiwan 1
Totale 7.114
Salva come PNG Salva come JPEG
Città #
Fairfield 502
Ashburn 483
Woodbridge 389
Singapore 337
Hong Kong 243
Houston 230
Seattle 219
Chandler 210
Cambridge 203
Beijing 192
Nyköping 186
Wilmington 186
Ann Arbor 123
Los Angeles 74
Lawrence 64
Jacksonville 60
Dallas 59
Roxbury 58
Ho Chi Minh City 52
New York 42
Jakarta 39
Nanjing 39
Des Moines 36
Bari 35
Chicago 31
São Paulo 30
Buffalo 29
Inglewood 28
Munich 28
London 27
Helsinki 26
Abidjan 24
Santa Clara 24
Dong Ket 23
Redwood City 21
Tokyo 20
Brooklyn 19
Brussels 19
San Diego 19
Paris 18
Nuremberg 17
Rome 17
Johannesburg 16
Warsaw 16
Brasília 15
Princeton 15
Belo Horizonte 14
Hanoi 14
Moscow 14
Turku 14
Dublin 13
Rio de Janeiro 12
Chennai 11
Düsseldorf 11
Boardman 10
Montreal 10
Shenyang 10
Toronto 10
Vienna 10
Dearborn 9
Mexico City 9
Nanchang 9
Stockholm 9
Changsha 8
Curitiba 8
Orem 8
Pune 8
Ankara 7
Atlanta 7
Elk Grove Village 7
Frankfurt am Main 7
Guangzhou 7
Vibo Valentia 7
Buenos Aires 6
Denver 6
Falkenstein 6
Hebei 6
Jiaxing 6
Lauterbourg 6
Milan 6
Ninh Bình 6
San Francisco 6
The Dalles 6
Amsterdam 5
Baghdad 5
Bologna 5
Boston 5
Can Tho 5
Casablanca 5
Columbus 5
Dhaka 5
Haiphong 5
Phoenix 5
Poplar 5
Porto Alegre 5
Ribeirão Preto 5
Salt Lake City 5
Shanghai 5
Taranto 5
Tianjin 5
Totale 4.951
Salva come PNG Salva come JPEG
Nome #
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors 220
Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity 158
Gastroenteropancreatic Neuroendocrine Tumors 157
Osteotropism of neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro 151
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study 149
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe 148
Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition 148
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 148
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression 146
Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations 141
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. 141
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications 141
New insights into the molecular pathogenesis of langerhans cell histiocytosis 140
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. 136
NETs: Organ-related epigenetic derangements and potential clinical applications 135
The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. 131
Erdheim-Chester disease: A systematic review. 122
An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. 121
Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors 116
Analysis of the immune landscape of small bowel neuroendocrine tumors 114
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 110
Lenalidomide in multiple myeloma: current experimental and clinical data 110
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors 109
Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition 108
The management of refractory carcinoid syndrome: challenges and opportunities ahead 108
The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors 107
Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease 105
Local treatment for focal progression in metastatic neuroendocrine tumors 102
A phase II study of axitinib in advanced neuroendocrine tumors 102
SNPs in predicting clinical efficacy and toxicity of chemotherapy: Walking through the quicksand 99
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials 97
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors 96
Radionuclide Therapy for Neuroendocrine Tumors 95
Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems 94
Effect of vitaxin on hyperactive osteoclastogenesis in multiple myeloma: a preclinical study 93
Cell fusion in myeloma marrow microenvironment: role in tumor progression 91
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer 91
DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors 90
Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice 88
Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. 87
Local treatment for focal progression in metastatic neuroendocrine tumors 87
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours 86
An update on gastroenteropancreatic neuroendocrine tumors 81
Novel Lenalidomide-based combinations for treatment of multiple myeloma 81
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 80
Therapy for locoregional disease: pancreas 79
1101MO Development of CAR T-cells for future treatment of NETs 77
In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients 75
An update on Merkel cell carcinoma 73
Higher frequency of isolated PMS2 loss in colorectal tumors in Colombian population: preliminary results 73
Management of NETs in the Precision Medicine Era 72
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 71
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 71
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 71
Non-Melanoma Skin Cancers: Biological and Clinical Features 71
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 70
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms 69
Sensitivity and Specificity of the NETest: A Validation Study 67
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 66
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 65
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment 65
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors 64
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 62
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 61
Lanreotide dopo octreotide LAR nel pNET in progressione: descrizione di un caso 61
Neuroendocrine tumors 61
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML 57
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours 55
EPB41L5 is Associated with the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors 54
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%? 54
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 51
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms 51
An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs 50
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 50
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 44
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 40
Is NETTER-2 a practice-changing trial? 32
A challenge in emergency department: a case report of oxaliplatin-induced Kounis syndrome 30
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France 25
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial 23
The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients 21
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM) 21
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence 20
In Defense of Neuroendocrine Tumor Trials 20
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study 17
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis 16
The future of cellular therapy for the treatment of renal cell carcinoma 14
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries 14
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 14
The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion 3
White paper on best practices for translational research in neuroendocrine neoplasms 3
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors 3
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? 2
Totale 7.488
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.503
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.503
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021470 0 0 0 0 0 87 68 90 33 95 43 54
2021/2022444 42 19 3 10 17 50 14 18 38 37 71 125
2022/2023636 91 111 47 31 37 92 19 87 82 2 17 20
2023/2024313 19 55 14 38 35 63 18 11 6 13 4 37
2024/20251.610 49 27 128 83 57 129 162 129 96 164 207 379
2025/20261.923 557 200 255 472 409 30 0 0 0 0 0 0
Totale 7.488